New Intravascular Contrast Agent Applied to Dynamic Contrast Enhanced Mr imaging of Human Breast Cancer
Article first published online: 12 MAY 2003
Volume 44, Issue 3, pages 275–283, May 2003
How to Cite
Rydland, J., BjØrnerud, A., Haugen, O., Torheim, G., Torres, C., Kvistad, K. A. and Haraldseth, O. (2003), New Intravascular Contrast Agent Applied to Dynamic Contrast Enhanced Mr imaging of Human Breast Cancer. Acta Radiologica, 44: 275–283. doi: 10.1034/j.1600-0455.2003.00068.x
- Issue published online: 12 MAY 2003
- Article first published online: 12 MAY 2003
- Accepted for publication 6 February 2003.
- Breast cancer;
- MR imaging;
- intravascular contrast agent
Purpose: To evaluate the feasibility of using dynamic contrast-enhanced MR imaging with a new intravascular contrast agent in grading human breast cancer.
Material and Methods: 23 patients with 27 breast tumors (21 carcinomas and 6 fibroadenomas) were examined with dynamic MR imaging after administration of Clariscan, an iron oxide nanoparticle with large T1 relaxivity and a long plasma half life. A 3D T1-weighted gradient echo sequence with an acquisition time of 60 s was repeated at regular intervals of 3–5 min before and up to 1 h after injection of 2 mg/kg b.w. of Clariscan. The endothelial transfer constant, Kps, which reflects overall vascular permeability, and the fractional plasma volume, fPV, were estimated from time-intensity curves acquired from three separate regions of interest (ROIs): whole tumor, a permeability hot spot, and a blood volume hot spot. Kps and fPV were compared to the results of histologic tumor grading (Scarff-Bloom-Richardson, SBR) and microvascular density, MVD.
Results: A statistically significant correlation between the MR-derived Kps parameters and the SBR score was obtained for the whole tumor ROI (R = 0.70), and for the permeability hot spot ROIs (R = 0.67). A correlation between fPV and SBR was detected for the blood volume hot spot ROIs (R = 0.48). There was no statistically significant correlation between Kps or fPV with MVD.
Conclusion: The results support the hypothesis that dynamic MR with the intravascular contrast agent Clariscan may be used for non-invasive tumor grading.